Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Berlex Yasmin 20 NDA Filing For Lower Estrogen Dose Slated For Q4

Jul 14 2003

• By The Pink Sheet

Related Content

FDA Hormone Therapy Outreach Will Stress Short-Term, Low-Dose Use

Mar 10 2003

BerlexYasmin Reps Likely To Promote Anti-Fluid, Androgen Effects

May 21 2001

Ortho Tri-Cyclen OC approved for acne treatment; Dermik's Klaron also cleared for acne.

Jan 06 1997

Wyeth Alesse

Jan 29 2001

Pfizer Estrostep

Jul 09 2001

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window